Show simple item record

dc.contributor.authorAngelis, V
dc.contributor.authorTippu, Z
dc.contributor.authorJoshi, K
dc.contributor.authorReis, S
dc.contributor.authorGronthoud, F
dc.contributor.authorFribbens, C
dc.contributor.authorOkines, A
dc.contributor.authorStanway, S
dc.contributor.authorCottier, E
dc.contributor.authorMcGrath, S
dc.contributor.authorWatkins, D
dc.contributor.authorNoble, J
dc.contributor.authorBhosle, J
dc.contributor.authorGerlinger, M
dc.contributor.authorHamid, I
dc.contributor.authorSoliman, H
dc.contributor.authorNenclares, P
dc.contributor.authorJones, R
dc.contributor.authorHarrington, K
dc.contributor.authorGennatas, S
dc.date.accessioned2020-07-17T10:04:20Z
dc.date.issued2020-09
dc.identifier.citationEuropean journal of cancer (Oxford, England : 1990), 2020, 136 pp. 99 - 106
dc.identifier.issn0959-8049
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3850
dc.identifier.eissn1879-0852
dc.identifier.doi10.1016/j.ejca.2020.06.027
dc.description.abstractBackground In light of the coronavirus disease 2019 (COVID-19) pandemic, cancer centres in the United Kingdom and Europe re-organised their services at an unprecedented pace, and many patients with cancer have had their treatments severely disrupted. Patients with cancer were considered at high risk on sparse evidence, and despite a small number of emerging observational studies, the true incidence and impact of COVID-19 in the 'at-risk' population of patients with cancer is yet to be defined.Methods Epidemiological and clinical data were collected prospectively for patients attending the Royal Marsden Hospital and three network hospitals between March 1st and April 30th 2020 that were confirmed to have Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection. Significance of clinical and pathological characteristics was assessed using the Fisher's exact test and Wilcoxon rank sum test, whilst univariate and multivariate logistic regression models were used to further assess risk. The number of patients attending in March/April 2020 for face-to-face attendances was also extracted.Findings During the 2-month study period, 867 of 13,489 (6.4%) patients met the criteria leading to swab testing. Of the total at-risk population, only 113 of 13,489 (0.84%) were swab positive, 101 of 13,489 (0.75%) required hospital admission and 29 of 13,489 (0.21%) died of COVID-19. Of the patients that attended the hospital to receive cytotoxic chemotherapy alone or in combination with other therapy, 59 of 2001 (2.9%) were admitted to the hospital for COVID-19-related issues and 20 of 2001 (1%) died. Of the patients that collected targeted treatments, 16 of 1126 (1.4%) were admitted and 1 of 1126 (0.1%) died. Of the 11 patients that had received radiotherapy, 6 of 1042 (0.6%) required inpatient admission and 2 of 1042 (0.2%) died.Interpretations Administration of systemic anticancer therapy appears to be associated with a modest risk of severe COVID-19 infection. Based on this snapshot taken as the first wave of COVID-19 hit our practice, we conclude that continuation of active cancer treatment, even in the palliative setting, is appropriate.
dc.formatPrint-Electronic
dc.format.extent99 - 106
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectHumans
dc.subjectPneumonia, Viral
dc.subjectCoronavirus Infections
dc.subjectNeoplasms
dc.subjectAntineoplastic Agents
dc.subjectProtein Kinase Inhibitors
dc.subjectHospitalization
dc.subjectRadiotherapy
dc.subjectIncidence
dc.subjectMortality
dc.subjectMultivariate Analysis
dc.subjectLogistic Models
dc.subjectRisk Factors
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectMale
dc.subjectCyclin-Dependent Kinase 4
dc.subjectCyclin-Dependent Kinase 6
dc.subjectYoung Adult
dc.subjectPandemics
dc.subjectPoly(ADP-ribose) Polymerase Inhibitors
dc.subjectUnited Kingdom
dc.subjectBetacoronavirus
dc.subjectAntineoplastic Agents, Immunological
dc.subjectCOVID-19
dc.subjectSARS-CoV-2
dc.titleDefining the true impact of coronavirus disease 2019 in the at-risk population of patients with cancer.
dc.typeJournal Article
dcterms.dateAccepted2020-06-24
rioxxterms.versionofrecord10.1016/j.ejca.2020.06.027
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2020-09
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfEuropean journal of cancer (Oxford, England : 1990)
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Translational Oncogenomics
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR/Students
pubs.organisational-group/ICR/Students/PhD and MPhil
pubs.organisational-group/ICR/Students/PhD and MPhil/20/21 Starting Cohort
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Translational Oncogenomics
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR/Students
pubs.organisational-group/ICR/Students/PhD and MPhil
pubs.organisational-group/ICR/Students/PhD and MPhil/20/21 Starting Cohort
pubs.publication-statusPublished
pubs.volume136en_US
pubs.embargo.termsNo embargo
icr.researchteamTranslational Oncogenomicsen_US
dc.contributor.icrauthorNenclares, Pabloen
dc.contributor.icrauthorGerlinger, Marcoen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0